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Aims: To assess the clinical and cerebrospinal fluid characteristics, and the 
role of tuberculous meningitis (TBM) as a confounder, in a cohort of HIV 
positive individuals with positive varicella zoster virus (VZV) positive 
cerebrospinal fluid PCR. 
Methods: Patients in the NHLS database at Groote Schuur Hospital with 
positive CSF VZV PCR who were also HIV co-infected and whose folders 
were available for clinical review were reviewed. Clinical and biochemical 
data were collected. Patients were divided into two groups based an 
accepted case definition for TBM. Differences between groups were 
assessed using Mann-Whitney U or Chi squared tests as appropriate.  
Results: There were 437 for VZV PCR over three years. Of these 98 were 
positive and, after exclusions, 31 HIV positive patients were included for 
further analysis. Median age was 31 and median CD4 count was 146 
cells/mm3.  11 (35%) had meningitis and 8(25%) had encephalitis. 13 (42%) 
met the case definition for TBM. Patients with CNS varicella were frequently 
confused whereas those with TBM presented sub-acutely.  There were no 
differences in CSF characteristics. Additional organisms were detected 6 
(19%) patients. 4 (13%) patients died in hospital. CSF TB culture was 
requested in 24 (77%) patients and extra CNS samples were sent in only 4 
patients.  
Conclusion: The clinical and CSF presentation of CNS Varicella and TBM 
overlap and in this cohort patients were under investigated for TB. In settings 
of high TB prevalence the possibility of false positive PCR or incidental 





Varicella zoster virus is an important human pathogen with several important 
neurological complications. The diagnosis of varicella has been 
revolutionised by the discovery of polymerase chain reaction (PCR) 
techniques. These tests have made rapid diagnosis possible facilitating faster 
treatment. The availability of these tests has led to an increasing number of 
case reports and case series of neurological illness caused by varicella in the 
absence of a rash. In addition several recent publications have highlighted 
the clinical presentation of neurological varicella and described in more detail 
the cerebrospinal fluid (CSF) characteristics of this infection. These cases 
and publications have largely been unaffected by the human 
immunodeficiency virus (HIV).  
Varicella reactivation as shingles and subsequent neurological complications 
is a common clinical problem in HIV infected patients. However these 
patients are also at risk of numerous other infections, many of which appear 
to have similar presentations and CSF characteristics. PCR techniques seem 
ideal for this situation.  
However, PCR techniques are not without their drawbacks. A number of 
studies have shown PCR detection of viral DNA in the CSF where clinical 
infection with that virus is judged unlikely. Again this has not previously been 
studied in HIV. 
In this thesis I discuss the pathogenesis of varicella infection, latency and 
reactivation and review the potential pitfalls of PCR diagnostic techniques in 
the setting of HIV. I then undertook a retrospective analysis the clinical and 
CSF characteristics of patients with HIV infections and a positive varicella 
CSF PCR. In addition I sought to identify potential co-infections, especially 
tuberculosis, potentially confounding the diagnosis.    
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Chapter 1: Literature review 
Varicella Zoster virus (VZV) is a common human pathogen. It is grouped 
together with other human herpes viruses (as Human herpes virus 3) and is 
one of the most frequently encountered viruses in clinical practice. It is best 
known for causing chicken pox and shingles but has been associated with 
several other clinical syndromes including post herpetic neuralgia, stroke, 
encephalitis and myelitis1. This chapter will provide an overview of the 
biology of VZV including mechanisms of immune evasion, techniques for 
laboratory diagnosis, and their pitfalls, as well as the evidence for VZV 




Infection with VZV is common and is characterised by primary infection 
causing chicken pox (varicella) and reactivation in later life causing shingles 
(zoster). It occurs worldwide. Primary infection (chicken pox) usually occurs 
in children and reactivation with shingles usually occurs in later adult life2. In 
temperate climates primary VZV infection occurs in seasonal epidemics in 
late winter and spring. This is most likely a result of respiratory spread of the 
virus2. This seasonal pattern is less marked in tropical climates where 
infection tends to occur throughout the year and in adolescence or early 
adulthood2. This age-related pattern is evident in sero-prevalence studies. In 
European countries sero-prevalence in 10-15 year olds tends to be high. For 
example in Sweden the seroprevalence of VZV in 12 year olds is 98%3. In 
contrast in Singapore it is only 60.5% amongst 7-12 year olds and increases 
to 84% among young adults (20-29)4. Data from Africa shows a similar 
pattern. In a study from Eritrea children over 5 had a sero-prevalence of 34% 
compared to 90-95% for adults5. 
Sero-prevalence in patients living with HIV is also high. In a recent study from 
South Africa the sero-prevalence of VZV was 89% in patients with HIV6. The 
mean age was 39 year old and the mean CD4+ count was 386 cell/mm3. 
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Interestingly only 20% of these cases reported a history of chicken pox and 
17% gave a history of a vesicular rash.   
Such high rates of seropositivity imply that most adults have VZV latent in 
sensory and autonomic ganglia. This has implications for diagnostic testing 
which will be discussed further in section 4.2.     
 
2. Varicella Zoster Virus – structure and function 
All herpes viridae are double stranded DNA viruses. Eight human herpes 
viruses (HHV) are known and these include herpes simplex (HHV1 and 2), 
Varicella Zoster virus (HHV3), Epstein Barr Virus, Cytomegalovirus, Human 
herpes virus 6 and 7 (causing Roseola) and Kaposi’s sarcoma associated 
herpes virus (HHV8)7.  This group is further divided in to α, β and γ sub-
families. HSV 1 and 2 and VZV constitute the α-Herpes virus group and are 
characterised by rapid replication and neuronal latency8.  
The VZV genome is 125 kb and is the smallest of the Human herpes 
viruses9. It encodes 70 genes 64 of which are shared with herpes simplex 
virus9. Five viral clades have been identified but 99.8% of the genome is 
preserved between clades10. The genome contains 5 repeat regions and 
differences in repeat length are used to distinguish different clades9,10.  
Glycoproteins are important for viral infectivity and intracellular assembly and 
function. This topic is extensively covered by Arvin and is summarised 
below9. At least seven glycoproteins are encoded for in the VZV genome. 
These are gB, gC, gE, gH, gI, gK and gL9. Glycoprotein B is important in viral 
fusion to cell membranes and for transport within the endoplasmic reticulum. 
Glycoproteins E and I are involved in viral replication9. Glycoprotein I serves 
as a chaperone protein regulating gE function and transport9, and is 
important in the formation of the cell membrane envelope and in golgi 
apparatus processing9. Glycoprotein I and E complexes also appear to 
increase tight junctions between host cell thus facilitating viral spread with the 
host. Glycoprotein E is also important in neurovirulence11.In particular 
formation of gE/gI heterodimers is essential for invasion of the dorsal root 
ganglion (DRG) in a knockout mouse model but  the mechanism of this is 
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unclear11. Glycoproteins H and L form complexes within the infected cell and 
facilitate viral egress9. Like gE/gI complexes, they also appear to enhance 
cell to cell fusion9. The function of gK is less clear. Experiments where the gK 
open reading frame (ORF) is deleted renders the virus non-infectious 9.  
VZV also has several regulatory proteins encoded on ORFs 4, 10, 61, 62, 63, 
70, 719. ORFs 62/71 and 63/70 are duplicated. These proteins perform 
several regulatory functions during viral replication. Protein 62 is a 
transactivator of transcription and also functions to upregulate several cellular 
proteins involved in promotion of transcription9. Proteins 4 and 66 are both 
involved in regulation of protein 62 activation and regulation9. In a simian 
model of latency ORF 63 protein is one of the early proteins expressed 
during replication and  appears to be the only protein expressed during 
latency12. Its presence in the DRG during latency may indicate low grade 
viral replication constrained by an effective immune system. 
 
3. Pathogenesis 
VZV is highly species-specific, a fact which has made studying its 
pathogenesis in animal models difficult.  It is also notoriously difficult to grow 
in culture. Several approaches have been developed to overcome these 
obstacles. A related virus simian varicella virus (SVV) can infect primates and 
is genetically and immunologically similar to human VZV13. Several 
researchers have studied SVV in primate models and extrapolated this 
information to human VZV. Another approach uses the SCID-hu mouse 
which is a knockout mouse model of severe combined immunodeficiency14. 
This allows human cells to be introduced and studied. This model allows 
human skin, ganglia and other cells to be grafted onto the mouse to examine 
the immune response and infective spread of VZV14,15.   
 
3.1 Primary infection 
VZV is acquired via aerosolised viral particles or direct contact with vesicle 
fluid where it rapidly invades the lymphoid tissue of the oro and 
nasopharynx2.  From these lymphoid tissues the virus spreads rapidly to 
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CD4+ and CD8+T lymphocytes16. The capacity for VZV to invade 
lymphocytes shows that VZV is lymphotrophic, in addition to its well-known 
neurotropism, a feature that may have relevance when interpreting diagnostic 
tests.  Infected lymphocytes spread to the peripheral circulation and 
contribute to the first of two viraemic stages17,18. From here the virus seeds 
into the reticuloendothelial system2. It has been more recently recognised, 
from studies in the SCID-hu mouse model, that following primary viraemia 
VZV also spreads to the skin where it remains during the latent phase14. This 
is driven by the preferential infection of activated memory CD4+ cells as well 
as lymphocytes expressing cutaneous lymphocyte antigen and chemokine 
receptor 414,16. These are skin homing markers facilitating viral infection of 
the skin.  The predilection of VZV for memory T cells is underemphasised in 
research on latency and reactivation. A population of VZV specific memory T 
cells will contribute to VZV immunity but whether these cells carry VZV DNA 
is not clear. However one study has shown VZV DNA in peripheral blood 
mononuclear cells in older adults19. No studies have examined this in HIV 
positive individuals.  
Initially the infection appears to be contained by the innate immune system. 
This is driven predominantly by interferon-α (IFN-α). VZV inhibits Stat 1 
which is a key phosphorylating enzyme in cellular production of IFN-α14. 
Without interferon-α natural killer cells cannot effectively target infected cells 
which then provide reservoirs for replication. Neighbouring cells can still 
produce IFN-α and this balance initially contains the infection16. This 
accounts for the latent phase of the infection which lasts from 7 to 21 days14. 
The innate immune response is eventually overwhelmed allowing further viral 
replication and the second viraemia following which the typical skin rash 
emerges14. The relatively long incubation period is partly accounted for by 
VZV’s ability to evade the innate response but it also effectively evades the 
cellular components of the adaptive immune response. Perhaps most 
importantly VZV disrupts major histocompatibility compatibility (MHC) 
signalling in infected cells9,16. It blocks interferon γ driven MHC-2 expression 
in infected cells, which interferes with the CD4+ T lymphocyte recognition of 
infected cells9. At the same time MHC-1 expression is also down regulated 
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thus evading the CD8 T lymphocyte cytotoxic response9,14,20. Although during 
initial skin infection the innate immune system contains the infection, VZV is 
able to inhibit apoptosis in infected cells thus sustaining intracellular 
replication14.    
These mechanisms of immune evasions allow the VZV infection to be more 
productive. It is during this stage that organ involvement, which may be sub-
clinical, occurs and the rash becomes clinically apparent2. Immuno-
competent hosts present with typical chicken pox with a centrifugally 
spreading vesicular rash often involving mucous membranes, and fever2. 
Immunocompromised hosts are more likely to develop severe organ 
involvement such as pneumonia and hepatitis21. Central nervous system 
involvement is infrequent but can present as a cerebellitis, meningitis, 
meningo-encephalitis, vasculitis and multi-dermatomal shingles13.         
 
3.2 Latency and reactivation 
Studying latency and reactivation of VZV has been challenging due to the 
lack of a suitable animal model and knowledge of these processes is still 
incomplete22. Much of the proposed pathogenesis is based on extrapolation 
from the SVV primate model and the SCID-Hu mouse model. Latency in 
sensory ganglia is a key feature of varicella infection. Following acute 
infection the virus becomes latent in the DRG, the sensory ganglia of the 
cranial nerves and autonomic ganglia 16,22. There are two main theories of 
how VZV infects these ganglia. The first is that following cutaneous infection 
the virus invades cutaneous sensory axons and spreads via retrograde 
axonal transport to the dorsal root ganglia16. The second theory is that during 
the viraemic phase infected T cells transport VZV to the dorsal root ganglia16. 
It is unclear why infected lymphocytes should show a predilection for the 
DRG. Evidence of infection of ganglia by lymphocytes or viraemia is mainly 
derived from research on SVV13. In this model, virus can be isolated from 
ganglia remote from cutaneous inoculation. DRG’s can also be infected 
following intravenous innoculation in both the simian and the guinea pig/ 
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SCID-Hu mouse model13. This phenomena has also been observed in 
humans following live virus vaccination23.  
Following infection of the DRG the virus establishes latency. During latency 
viral gene production is less restricted than has been previously thought. 
Recent studies have shown that as many as 10 viral proteins are expressed 
during latency in both humans and primates12,24. The role of these expressed 
genes and proteins in maintaining latency is unclear. The most abundantly 
expressed protein appears to be that of ORF 63 which is also prominently 
expressed in the early lytic phase of primary infection and reactivation12,24,25. 
Whether this represents low level replication transiently escaping CD4+ cell 
suppression or plays some other role in sustaining latency is unclear. 
However, the abundant expression of this and other proteins raises the 
question of whether the virus is truly latent or merely undergoing restrained 
low level replication. The viral load in ganglia is low but measurable 
suggesting that replication is indeed persistent, in contrast to herpes simplex 
virus20,26. Viral latency is probably maintained by several mechanisms 
including epigenetic suppression of the viral genome and cell mediated 
immunity26,27,28. Interestingly, depletion of B cells and CD8+ cells does not 
impair the establishment of latency28. Although the exact mechanism of the 
transition from latency to replication is unclear, it is linked to declining cell 
mediated immunity, particularly loss of CD4+ cells29. This dual role of CD4+ 
cells, being essential to both establishing latency and in preventing 
reactivation, is intriguing and has not been adequately studied.   
In addition to being present in the DRG during latency, VZV DNA can also be 
isolated from peripheral blood monocytes (PBMs) in otherwise healthy, 
elderly humans19. Whether this represents latency in lymphocytes or just 
transient reactivation (discussed below) is unclear. This finding has not been 
replicated and has not been studied in HIV infected patients. Newer evidence 
suggests that VZV can infect and be maintained in T cells although latency in 
these cells has not been shown20. It is more likely that the finding of virus in 
peripheral blood lymphocytes may be indicative of sub-clinical reactivation 
and spread without symptoms. 
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Reactivation of VZV is dependent on a reduction in the effective CD4 
response30. This can occur in the setting of immunodeficiency, such as 
human immunodeficiency virus (HIV) infection, with reduced effective 
immunity in the setting of another illness, such as malignancy or tuberculosis, 
or with normal aging31,32. Inflammatory cytokines may also be involved in 
triggering reactivation16. The initial feature of reactivation is increased 
transcription within the DRG12,33. This results in an inflammatory reaction 
which may be severe, haemorrhagic and result in spread of viral particles to 
adjacent tissues including, possibly, the cerebrospinal fluid (CSF)12. 
Following this, virus spreads via axonal transport to the skin in the innervated 
dermatome12,32. Clinical reactivation of VZV typically presents as shingles 
with a dermatomal or multi-dermatomal vesicular skin rash2. The rash is 
frequently preceded by pain in the dermatome, which may be severe32. Pain 
persisting for more than three months following infection is known as post-
herpetic neuralgia and is a common complication8. When VZV reactivation 
occurs in the absence of rash it is known as zoster sine herpetica34.  
Reactivation as shingles is rarely recurrent in healthy individuals. Recent 
evidence suggests that latent VZV may undergo periodic increases in viral 
replication that seems to exist on a spectrum from DNA merely being present 
in the DRG to sub-clinical reactivation to zoster sine herpetica30. The idea of 
fluctuating immunity and reactivation was suggested as part of the 
pathogenesis of shingles as early as 195935. Supporting this proposed 
argument VZV DNA has been found in otherwise healthy individuals in both 
their saliva and peripheral blood monocytes13. This is probably more frequent 
in immunocompromised individuals and has implications for the diagnosis of 
VZV as the cause of a clinical syndrome in the absence of a typical rash36,37.  
 
3.3 Complications of reactivation 
Reactivation has been associated with a number of complications. Trigeminal 
nerve involvement can lead to zoster ophthalmicus with corneal ulceration 
and blindness16. Immunocompromised patients are also at risk of hepatitis 
and pneumonia16. Neurological complications are frequent and may be 
particularly severe in the immunocompromised individual. The most common 
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is post-herpetic neuralgia which may occurs in up to 40% of patients and can 
be very difficult to treat effectively8. Neurological involvement can also 
present as meningitis, meningo-encephalitis, myelitis, cerebellitis and 
vasculopathies38.  
 
4. Varicella related neurological syndromes 
 
4.1 Diagnosis 
The diagnosis of viral infections was revolutionised in the late 1980’s with the 
development of polymerase chain reaction (PCR) techniques39. Prior to this 
the diagnosis of viral infections relied on viral culture or serological testing. 
VZV is particularly difficult to culture partly because it remains attached to the 
cell membranes during much of its replication cycle39. The process is also 
labour intensive and difficult to automate39.  
Serological testing is available but as the immunoglobulin response lags 
behind the clinical illness, the results are often only useful in retrospect2. The 
relevance of a positive blood serology to a central nervous system (CNS) 
infection is also sometimes uncertain especially in diseases, such as multiple 
sclerosis and HIV infection, where a polyspecific immune response is present 
(generalised increase in immune components directed against multiple 
antigens which may not be relevant to the illness) 40. One strategy that is 
used in this circumstance is to determine a virus specific serum:CSF IgG 
index41. By comparing levels of virus specific antibody in the CSF and in the 
blood one can demonstrate higher immunoglobulin in CSF compartment. 
This is often used as evidence of productive infection of the CNS and can be 
quantified to improve diagnostic utility40.    
Molecular diagnostic testing is integral to diagnostic virology and there are 
several PCR techniques that are useful in the diagnosis of VZV42. Qualitative 
PCR detects the presence or absence of virus whereas quantitative PCR 
detects the amount of virus present as a viral load. Multiplex PCR panels, 
which can simultaneously screen for many pathogens, are used increasingly 
in the diagnosis of clinical syndromes with multiple potential infectious 
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aetiologies (such as encephalitis)43. These panels typically test for several 
common organisms. They are sensitive and the appeal of using one test to 
distinguish between several infections in a situation requiring speedy 
diagnosis is undeniable. However, with this ease of testing the clinical 
interpretation of these tests becomes an important issue.  
 
4.2 Pitfalls in diagnostic testing 
For the most part these tests are useful in diagnosing infection by VZV. 
However there are some caveats to be considered in the clinical 
interpretation of these results in certain circumstances.  
4.2.1 CSF:Serum VZV IgG index  
The CSF: serum VZV IgG index is regarded by many authors as the gold 
standard by which to diagnose VZV infection of the CNS with the caveat that 
testing should not be performed in the first week of the illness38,44. This test 
has never been validated against brain biopsy but the principle appears 
intuitive. Namely if the antibodies to a specific virus are present in a higher 
concentration in the CSF than in the serum this must imply CNS infection. 
There are however several mechanisms and circumstances in which this 
argument may not hold true.  
Firstly a polyclonal humoral and cellular immune response is elicited in many 
inflammatory conditions including HIV and Multiple sclerosis (MS)45,46,47. 
Memory B cells are stimulated to produce antibodies either by specific 
stimulation by CD4+ cells or by non-specific cytokines as part of a broad 
inflammatory response47,48. A recurring theme in the MS literature is the 
association with antibodies in the CSF directed against various viruses. 
Some authors believe that this is evidence of a viral trigger to MS but this 
remains unproven. The fraction of antibody in the CSF has been shown to be 
higher in VZV reactivation than in MS and it has been suggested that this 
may be useful to discriminate between non-specific activation and active 
infection47. There are, however, no reference ranges with which to make this 
distinction in individual patients. Furthermore patients may have positive CSF 
IgG indexes to more than one virus48. In some cases this is due to similarities 
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between the viruses (eg VZV and herpes simplex) but this also occurs in MS 
and other situations where viral infection is unlikely. Of particular importance 
in Sub-Saharan Africa is that the performance of these tests has not been 
studied in HIV infection. In the setting of HIV infection the IgG index is 
commonly elevated as part of the polyclonal immune activation and this is 
quite likely to produce false positive serological tests49,50. Birlea et al 
analysed VZV IgG index on 180 HIV positive patients with a range of 
neurological problems37. Of these 28 were positive (16%) and 24 had no 
clinical evidence of current or preceding VZV.  
It is uncertain whether or not the elevated viral specific VZV IgG index 
indicates previous active, as opposed to sub-clinical, reactivation. VZV has 
been detected in asymptomatic HIV negative individuals and HIV positive 
individuals with neurological problems judged unlikely to be due to 
VZV51,52,19. This combined with the detection of protein 63 in ganglia, 
suggests that VZV replication is suppressed by active T cell regulation but 
that the course of infection is characterised by periodic viral escape and re-
suppression. In the context of HIV infection reactivation may evoke a more 
pronounced inflammatory response. Given that the site of latency (in the 
DRG) is so closely related to the CSF it is not clear that such reactivations 
may not initiate an antibody response in the CSF compartment without 
necessarily indicating active infection. Further investigation of this potential 
mechanism seems important but technically difficult.       
 
4.2.2 PCR 
PCR is a valuable and powerful tool in the diagnosis of infectious disease. 
Improvements in PCR have enabled detection of minute quantities of viral 
DNA and with the development of real-time quantitative PCR (qPCR) the 
speed of processing of these results has dramatically increased53,54. 
However, the features which make it such a powerful tool also introduce a 
need for caution in the interpretation of PCR results. There are several 
potential technical problems with PCR including problems with pre-assay 
conditions, specimen handling, primer choice and assay design53. It is 
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important that these technical factors are addressed but a more relevant 
consideration for clinicians is the distinction between a laboratory true 
positive and a clinical true positive result. The very sensitivity of PCR means 
that tiny amounts of DNA are amplified giving a laboratory true positive53. 
However this may be either a clinically true or false positive. DNA from 
infectious organisms may present in a sample for multiple reasons; even 
from a site traditionally regarded as sterile, such as the CSF. 
Davies et al performed an elegant study where they reviewed CSF samples 
over a four year period and used a multiplex PCR for a range of potential 
neurotropic organisms including herpes viridae55. They also reviewed 
patient’s clinical records and, using strict criteria, estimated the likelihood of a 
CNS infection. They sought to determine factors influencing negative and 
positive PCR results. Interestingly the multiplex PCR was positive in 15 of 
291 samples (5%) where CNS infection was judged unlikely. In 4 patients 
these results were in patients with an unequivocal alternative non-viral 
infection (meningococcal, cryptococcal and leptospirosis meningitis) and 3 
were from HIV positive patients with no evidence of a CNS infection. In 
addition multiple pathogens were detected in 12 patients (2%). These were 
mostly EBV and CMV and were in the groups where clinical CNS infection 
was judged likely or probable. Thus in their study the problem of multiple 
positive results occurred in the groups where the difficulty of determining 
which organism was responsible was greatest and where clinical features did 
not appear to be helpful in determining the cause. The authors suggest that 
DNA may be present in the CSF as a result of carriage in lymphocytes 
(Trojan horse hypothesis) or due to blood brain barrier disruption as part of 
another infection.    
VZV DNA is also frequently present in the CSF in uncomplicated shingles, 
that is, with no clinical evidence of CNS involvement56. In the study by 
Haanpää et al PCR was positive in 10/42 (24%) of patients with 
uncomplicated shingles and in one patient this was the only CSF 
abnormality56. This study was performed using older PCR techniques and it 
is likely that with more sensitive PCR techniques the rate of positive PCR 
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may be even higher. The prevalence of HIV in this study was not reported 
but, as the study was conducted in Finland, it was probably low. 
The issue is even more problematic in HIV infection. Shingles is common in 
HIV infected individuals, and frequently co-occurs with other infections due to 
impaired cell mediated immunity and dysregulated humoral immune 
system6,57. There are to date no studies assessing PCR positivity in 
uncomplicated shingles in HIV. However, following shingles, long term viral 
shedding has been detected in the saliva and blood of HIV positive patients 
even in the absence of clinical infection 58,59. Studies of PCR in CSF of HIV 
positive patients with neurological disorders highlight frequent detection of 
VZV DNA, usually ascribed to sub-clinical reactivation of VZV36,60. In the 
study by Burke et al they concluded that VZV PCR was a useful clinical 
tool60. Nine of the 81 HIV-infected patients were VZV positive and 3 were 
positive for both VZV and CMV. The presentations in the former included 
those likely to be related to VZV (radiculomyelitis, necrotising 
leukoencephalopthy) as well as less definite presentations (encephalitis and 
aseptic meningitis). In the dual positive cases the presentation could have 
been due to either virus. Five of 9 positive patients had shingles at 
presentation. However, in another study, authors concluded that sub-clinical 
reactivation was more common36. In this study 13/ 531 samples were VZV 
PCR positive and an alternative diagnosis was made in 9/13. All 13 had 
CD4+ counts less than 50. Multiple viruses were detected in 3 cases all of 
whom had an alternative diagnosis unrelated to either virus. A recent study 
from Zambia reported similar findings. Siddiqi et al analysed CSF samples 
from 331 HIV infected adults with symptoms of CNS opportunistic 
infections61. Multiple infections were found in 36% of cases. Herpes viruses, 
most commonly EBV, were common co-pathogens. Interestingly they 
reported 3 cases where VZV PCR was positive with TBM.  
From these studies it seems clear that the interpretation of PCR results 
needs a great deal of caution and careful consideration of other CSF 
parameters and clinical factors. CSF parameters are unfortunately also 




5. Tuberculous meningitis and VZV CNS infection 
Perhaps the most important differential diagnosis in this setting of high TB 
prevalence is tuberculous meningitis (TBM). TBM lacks an adequate 
diagnostic test and thus is frequently treated on clinical suspicion62. Tests 
traditionally used to diagnose TBM include CSF Ziel-Nielsen (ZN) and 
auramine staining for microscopic detection and CSF TB culture63. Bacilliary 
load is often low in TBM and thus the yield of microscopy is low. Culture 
performs betterwith yields of up to 60%,though this requires a large volume 
of CSF63. The organism is slow growing and thus results typically take 2-6 
weeks. This period is too long to aid in immediate treatment decisions but 
does confirm the diagnosis. Newer techniques such as TB PCR are 
available. They provide a rapid result but are still volume dependent and 
have sensitivities ranging between 60 and 80%64,65,66. This test has a modest 
negative predictive value limiting its clinical usefulness64,66. To get around 
these diagnostic problems, research studies have defined TBM using 
composite scoring systems incorporating clinical case definitions 
andlaboratory and imaging parameters67. A standardised case definition was 
recently produced by a panel of experts62. While this is useful, it is 
cumbersome to use in clinical practice and may not be sufficiently sensitive in 
detecting atypical cases that can reasonably be excluded from research 
studies but may still require treatment.   
Against the backdrop of these diagnostic difficulties care must be taken in the 
clinical investigation of meningitis and meningo-encephalitis which may be 
compatible with TBM, especially in areas of high prevalence. A positive result 
on another diagnostic test may distract from treatment of TBM where it is the 
true pathogen. Thus knowledge of the limitations of these tests is important 
for clinicians. 
A further confounding factor is that TBM itself may predispose to VZV 
reactivation. TB impairs cell mediated immunity and reduces CD4+ 
count28,68,69.  As discussed above these factors predispose to VZV 





In conclusion varicella is a ubiquitous virus. It commonly causes primary 
infection as chicken pox and may be reactivated as shingles. In addition it 
can cause several important neurological complications. Following primary 
infection the virus establishes latency but may undergo periodic attempts at 
replication. Active cell mediated immunity is required to limit this. As the 
viruses establishes latency in the dorsal root ganglion, and may have 
prolonged shedding in HIV, DNA may be present in biological fluids without 
clinically relevant infection. Although PCR is a useful test to diagnose a range 
of infections, it may be too sensitive in the setting of human herpes virus 
infections including VZV. This is highlighted by the detection of the virus in 
circumstances where active infection is judged unlikely (a clinical false 
positive). A positive result in this circumstance may distract a treating 
clinician from a more relevant, but difficult to diagnose condition, such as 
tuberculosis. Conversely there are situations where VZV is the primary 
infection and where treatment is required. Multiple infections are not 
uncommon in HIV further complicating these decisions.  
To date there are no studies in the setting of high HIV and TB prevalence 
examining differences in the clinical and laboratory presentations of these 
diseases. As a first step in addressing this problem we set out to describe the 
clinical and cerebrospinal fluid characteristic of HIV positive patients that 
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Abstract: 
Aims: To assess the clinical and cerebrospinal fluid characteristics, and the 
role of tuberculous meningitis (TBM) as a confounder, in a cohort of HIV 
positive individuals with positive varicella zoster virus (VZV) positive 
cerebrospinal fluid PCR. 
Methods: Patients in the NHLS database at Groote Schuur Hospital with 
positive CSF VZV PCR who were also HIV co-infected and whose folders 
were available for clinical review were reviewed. Clinical and biochemical 
data were collected. Patients were divided into two groups based an 
accepted case definition for TBM. Differences between groups were 
assessed using Mann-Whitney U or Chi squared tests as appropriate.  
Results: There were 437 for VZV PCR over three years. Of these 98 were 
positive and, after exclusions, 31 HIV positive patients were included for 
further analysis. Median age was 31 and median CD4 count was 146 
cells/mm3.  11 (35%) had meningitis and 8(25%) had encephalitis. 13 (42%) 
met the case definition for TBM. Patients with CNS varicella were frequently 
confused whereas those with TBM presented sub-acutely.  There were no 
differences in CSF characteristics. Additional organisms were detected 6 
(19%) patients. 4 (13%) patients died in hospital. CSF TB culture was 




Conclusion: The clinical and CSF presentation of CNS Varicella and TBM 
overlap and in this cohort patients were under investigated for TB. In settings 
of high TB prevalence the possibility of false positive PCR or incidental 
varicella reactivation should be considered. 
 
Introduction: 
Varicella Zoster virus (VZV) infection has been implicated in diseases of the 
central nervous system (CNS) such as encephalitis, meningitis, myelitis and 
strokes, and may in addition trigger immune-mediated disorders like acute 
demyelinating encephalomyelitis (ADEM). It is well known that active VZV 
disease may occur without the characteristic rash making the diagnosis 
challenging1.  Conversely VZV may reactivate in the setting of other illnesses 
(such as malignancy) where it does not directly contribute to the disease. 
Prior to the introduction of polymerase chain reaction (PCR) techniques, 
definitive diagnosis of VZV CNS infection rested on viral culture, brain biopsy, 
or the demonstration of a virus-specific intrathecal antibody response, 
methods that either lack sensitivity or fail to provide an answer within a 
clinically useful time frame2.  Newer PCR methods of detecting viral DNA in 
the cerebrospinal fluid (CSF) have improved the diagnostic sensitivity for 
VZV infection in the CNS and also expanded the clinical spectrum of VZV 
disease1.  An example is that VZV is now recognised as a common cause of 
aseptic meningitis in adults even without a rash. The clinical interpretation of 
CSF PCR results is however not without pitfalls. Firstly not all PCR assays of 
CSF pathogens have been compared against a gold standard. For example, 
only herpes simplex and JC virus CSF PCR tests have been validated 
systematically against brain biopsy. Secondly it is not clear that detection of 
viral DNA in the CSF necessarily represents active, clinically relevant 
infection. Concerns have been raised about both laboratory and clinical false 
positive PCR results. Quereda et al reported positive PCR in the CSF of HIV 
positive patients where a clinical viral infection was deemed unlikely3. Davies 
et al reported both false negative and false positives in the CSF with a 
multiplex PCR4.  The accuracy of a diagnostic test is particularly important in 
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illnesses which share clinical and CSF features such as VZV and TB 
meningitis. However, adequately validated, accurate laboratory diagnostic 
tests are lacking in both of these conditions. 
The clinical and CSF characteristics of active CNS VZV infection have 
recently received renewed attention5,6,7. Several authors have reported that 
VZV remains a frequent cause of CNS disease and most commonly presents 
as meningitis or encephalitis. Less than half of these patients have a rash or 
fever. The CSF usually shows an elevated white cell count (lymphocyte 
predominant) with raised protein5,6,7.  
Almost all studies reporting the range of clinical and CSF features of CNS 
varicella have been from areas with a low prevalence of HIV and TB where 
co-infection is an infrequent clinical concern. Consequently, it is not clear 
whether these features apply to HIV positive patients. One recent study from 
Malawi did not find a single case with positive CSF VZV in a cohort of mainly 
HIV positive patients with suspected meningitis8. We note, however, that 
patients in this study with confirmed bacterial, fungal or tuberculous 
meningitis were not tested for VZV, and so ‘dual’ infection was not reported.  
The brunt of the HIV and TB epidemics is in Sub-Saharan Africa where 
resources are limited5,6,7. PCR diagnostics are expensive and if the diagnosis 
is incorrect may lead to further expensive inappropriate treatment. It is 
therefore important to try and identify clinical or laboratory features 
suggestive of CNS Varicella to allow more cost effective use and 
interpretation of VZV PCR and appropriately direct treatment. We aimed 
therefore to describe the clinical and laboratory characteristics of HIV 
infected patients with positive CSF VZV PCR, in order to identify features that 
may discriminate between infectious causes of meningitis in this population. 
Methods:  
We retrospectively collected data on all CSF samples sent for VZV PCR 
testing to the National Health Laboratory Service (NHLS) laboratory at 
Groote Schuur Hospital during the study period from May 2008 and August 
2011. VZV PCR testing was performed on CSF according to standard 
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protocols at accredited laboratories. Laboratory data were extracted from the 
NHLS database. Cases with positive CSF VZV PCR from hospitals within our 
clinical service area were included for folder review. Cases were excluded if 
requests were submitted on fluids other than CSF or where the origin of the 
tested fluid was unclear. Where multiple samples were positive on the same 
patient, the admission CSF parameters were recorded. Detailed clinical data 
were obtained retrospectively from the hospital records by a clinician (AS), 
where hospital notes were available. The following information was recorded 
for the clinical episode: presence of fever(>37.5 ̊C), headache, meningism, 
seizures, rash, focal neurological signs and altered level of consciousness. 
Clinical signs of immunocompromise, pulmonary and extrapulmonary 
tuberculosis or other opportunistic infection were recorded. Brain imaging by 
computed tomography (CT) or magnetic resonance imaging (MRI) , chest 
radiography and abdominal ultrasound or CT examinations performed during 
the hospital admission were reviewed where source images were available, 
or reports were recorded. CSF white cell count (WCC), total protein, glucose, 
culture and other PCR results were recorded for each CSF sample. In 
addition CD4+ cell count and white cell count were also recorded.  
Patients were categorised by whether they presented clinically with 
encephalitis, meningitis, myelopathy, stroke or radiculopathy.  Encephalitis 
was defined as a febrile illness with altered level of consciousness or seizure 
on presentation, with or without focal signs other than paraparesis. Fever 
was defined as temperature greater than 37.5⁰ on admission. Altered level of 
consciousness was defined as a Glasgow Coma Score of 14 or less. 
Meningitis was defined as a febrile illness with headache and an abnormal 
CSF without altered level of consciousness, paraparesis or seizures.  
Myelopathy was defined as the acute onset of bilateral limb weakness which 
the attending clinician considered consistent with spinal cord lesion. Stroke 
was defined as the acute onset of focal neurological signs. Radiculopathy 
was defined as an acute radicular pain with or without a blistering rash. Any 
conflict in categorisation was resolved by consensus between authors.  
Patients were classified into definite or probable TBM based on an 
internationally accepted case definition9. Briefly: patients were classified as 
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having ‘Definite TBM’ if CSF smear was positive for acid fast bacilli (AFBs) or 
CSF cultured mycobacterium tuberculosis. ‘Probable TBM’ was diagnosed in 
patients with AFBs identified or mycobacterium tuberculosis cultured from 
specimens outside the CNS, or with imaging findings highly suggestive of 
tuberculosis (on brain imaging, chest radiograph or abdominal ultrasound). 
For the purposes of analysis, because of low numbers of microbiologically 
confirmed cases, ‘Definite’ and ‘Probable TBM’ was analysed together as 
‘Probable TBM’. All other patients were classified as CNS varicella. 
Data was analysed using SPSS 22 (IBM Corporation, USA). Due to the small 
sample size and non-normal distribution of the data continuous variables 
were analysed using the Mann-Whitney U test and ordinal/ nominal data was 
analysed using Chi squared test. Ethical approval for the study was obtained 
from the University of Cape Town Human Research Ethics Committee (REC 
Reference no. 01/2015). 
Results 
Over a 3 year period there were 437 requests for VZV on CSF registered on 
the laboratory database of which 98 were positive for VZV PCR. 57 patients 
were excluded (see study profile). Of the remaining 37 cases, 31 were HIV 
positive and thus included in further analysis. The median age was 31 years, 
the median CD4+ cell count was 146 cell/mm3 and 61% were female. 13 
(42%) patients met the case definition for probable TBM. In terms of clinical 
presentation 11 (35%) patients presented as meningitis, 8(25%) as 
encephalitis, 6(19%) as myelopathy and 5(16%) with strokes. There was no 
difference between the probable TBM and CNS varicella groups with respect 
to clinical presentation (p=0.157).  26 patients (83%) presented with rash and 
there was no difference between the TBM and CNS Varicella groups 
(p=0.924). 8 patients (26%) presented with confusion and patients in the 
CNS varicella group were more likely to be confused (p=0.05). Patients in the 
TBM group were more likely to have a sub-acute presentation with a median 
duration of illness of 9 days compared to 3 days in the CNS varicella group 
(p=0.21). There were no differences between groups with respect to fever on 




In terms of cerebrospinal fluid (CSF) analysis the median protein 
concentration was 1.81g/dl and median glucose concentration 3.1mmol/l. 
The median lymphocyte count was 51(range 0 - 970) and median neutrophil 
count was 3.5 (range 0 - 300). There were no differences in any of these 
parameters between groups. TB culture was requested in 24 cases (77%). 
No cultures were positive but one case was smear positive for acid fast 
bacilli. Extra-CNS TB samples were sent in only 4 patients, one of whom a 
positive sputum culture with a negative M.TB PCR. Additional organisms 
were detected in the CSF in 6 patients as follows: Treponema pallidum (1), 
Cryptococcus (1), Epstein-barr virus (2) and cytomegalovirus (2). Twenty-one 
(68%) patients had chest radiograph or abdominal ultrasound to investigate 
for extra-CNS TB. Nine (43%) of these had features suggestive of TB. Ten 
(32%) patients had no record of imaging studies performed. 
Twenty-three (74%) patients were treated with Acylovir and seventeen (55%) 
were treated with anti-tuberculous therapy. Fifteen (48%) patients were 
treated with both acyclovir and TB treatment. In the acyclovir group nine 
patients were started on intravenous therapy and switched to oral therapy, 
and three were treated with oral therapy alone. One patient was treated with 
TB treatment and antibiotics. In the Probable TB group, 8/13 (62%) were 
commenced on TB treatment and 11/13 (84%) on acyclovir. In the CNS 
varicella group, 9/18 (50%) were started on TB treatment, and 15/18 (83%) 
on acyclovir.   
4 (13%) patients died in hospital and there was no difference in mortality 




In this retrospective study 42% of patients with positive CSF VZV PCR met 
current case definitions for probable or definite TBM. Patients with TBM had 
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a longer duration of illness prior to presentation and those in the CNS 
varicella group were more likely to be encephalopathic. Apart from these 
features there were no differences in the clinical presentation or CSF 
characteristics to distinguish the two groups. Despite the high prevalence of 
TB in the communities studied the level of investigation for tuberculosis was 
quite low; possibly because finding the VZV rash or positive CSF PCR 
directed the clinical suspicion towards VZV. This is concerning given the high 
morbidity and mortality associated with TBM. Importantly rash was as 
common in the TBM group as the VZV group. 
Reactivation of VZV manifesting as shingles is a common occurrence in 
people who are living with HIV. Sub-clinical ‘reactivation’ has been described 
in the setting of HIV10. These cases were detected by CSF PCR or IgG index 
and these results were felt to indicate active CNS infection in the absence of 
clinical features. However, in recent years there have been positive CSF 
PCR results detected in patients in whom a replicative VZV infection of the 
CNS is thought unlikely, particularly in HIV infected patients11. This further 
complicates the interpretation of CSF PCR results and it would be helpful to 
know what clinical and CSF features raise the clinical suspicion of active, and 
clinically relevant, VZV infection. However the manner in which HIV 
influences the clinical and cerebrospinal fluid (CSF) features of VZV infection 
of the CNS is not clear.  Our study suggests that in the setting of HIV the 
CSF features of VZV are similar to those of TB. Given the absence of a 
highly accurate diagnostic test for TBM, an alternative explanation may be 
that detection of VZV DNA occurs more readily in patients with a concurrent 
infection such as HIV or TBM. CD4+ lymphocytes seem pivotal in controlling 
both primary infection, reactivation and possibly latency12,13. In its own right 
TB reduces CD4+ and thus predisposes to VZV reactivation14,15. A recent 
study from India examined CSF and brain tissue from 55 HIV positive patient 
who came to post mortem with confirmed TBM, Cryptococcal meningitis or 
CNS toxoplasmosis16. In this study 82% had a positive CSF PCR for a 
herpes virus and 45% had more than one positive PCR. Varicella was 
detected in 3.6%.   
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Sub-clinical detection of immunological evidence (elevated IgG or IgG ratio) 
of VZV in the CSF has also been described in HIV11,17. Whether or not this 
indicates clinically relevant disease is unclear. It is possible that virus specific 
IgG may be elevated due to the polyspecific immune activation in HIV. 
Detection of immunoglobulins directed against various viruses has been 
detected in the context of other neurological diseases characterised by 
polyspecific immune activation such as multiple sclerosis (MS). For example 
IgG to several viruses have been detected in the CSF of MS patients 
prompting speculation that a viral infection is responsible for triggering MS18. 
However most authors suggest that these IgG are detected as 
epiphenomenon, possibly upregulated in the setting of more general 
inflammation18. It is of interest that viral DNA has also been recovered from 
the CSF of MS patients who did not have an active viral CNS infection19. 
Another explanation for the relative increase of CSF IgG is that that patients 
with HIV may experience more vigorous local reactivation of VZV in the 
dorsal root ganglion as a resulted of impaired cell mediated immunity. This 
would result in breakdown of the blood brain barrier resulting in exposure of 
the CSF compartment to antigen. This may in its own right be sufficiently 
inflammatory to induce a CNS immune response without necessarily 
progressing to active CNS disease. There is to date no evidence for this 
hypothesis. 
There are also several reasons why viral DNA may be present in the CSF 
without active infection. Davies et al report up to 25% of general viral PCR 
results to be positive in settings judged unlikely to represent CNS infection 
(i.e. indicate false positive results)4. In that study, 13% of the cohort were 
known to be HIV positive; much lower than the HIV prevalence in sub 
Saharan Africa, which in hospital based meningitis cohorts ranges between 
70-90%. They suggest that clinical false positive PCR’s may occur due to a 
technical laboratory error. A positive PCR could also represent an 
epiphenomenon of reactivation of latent viruses in the setting of an 
immunological stressor or impaired cell mediated immunity. In either case the 
significance of a positive result becomes a clinical judgement. This is 
highlighted in their study by the relatively high incidence of EBV detection 
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considered unlikely to be causal. Low levels of EBV and CMV DNA in the 
CSF of HIV positive patients are not uncommon and a viral load may help 
determine clinical significance20. This was also observed in our study with 
both EBV and CMV DNA being detected in several patients. Two patients 
also had clear evidence of an alternative pathogen more likely to be clinically 
significant (neurosyphilis and cryptococcal meningitis) supporting the 
assertion that the reactivation of VZV was incidental. However, it is not 
uncommon for patients with late HIV infection to present with multiple 
concurrent opportunistic infections.  
Given the immune dysregulation that accompanies HIV, tuberculosis (TB) 
and the IRIS phenomenon the interpretation of immunoglobulin and PCR 
based tests in the setting of high HIV/ TB co-infection needs to be 
interrogated; especially in light of the arguments presented above.  
In our study PCR was commonly positive in patients with CNS disease, often 
in patients who had normal CSF parameters, no rash or clinical features of 
primary varicella or reactivation (zoster). These could reflect a false positive 
result or viral reactivation which may not be clinically relevant. The difficulty in 
interpretation of CSF findings is compounded by the fact that, in HIV, 
baseline CSF inflammation is frequently high with a background pleocytosis 
and elevated IgG index. Acting on a positive PCR results may result in 
inappropriately stopping TB treatment where TB is the actual primary 
infection. Our study suggests that it may be difficult to distinguish between 
CNS infections on clinical grounds. A rash may be present but this does not 
necessarily implicate VZV as the primary pathogen as has been discussed. 
CSF parameters are non-specific. 
Lastly the role of VZV in HIV positive stroke needs careful interrogation. 
While there have been clear and elegantly demonstrated cases of VZV 
vasculitis causing stroke it is unclear how HIV influences this association. As 
highlighted in this study HIV positive stroke patients with no clinical suspicion 
of VZV and normal CSF parameters are frequently PCR positive.    
Our study does have limitations. Firstly it is a retrospective study and workup 
of the cases varied and was incomplete in several cases. Secondly the 
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reference standards for the diagnosis of TBM and VZV CNS infection remain 
suboptimal. Lastly resources did not allow further analysis and comparison to 
the VZV negative CSF PCR’s.  
In conclusion the interpretation of CSF VZV PCR and IgG is not as clear cut 
as it would initially seem. While a positive PCR does show the presence of 
viral DNA in the CSF this may not always equate to clinically significant 
active infection. Similarly there are several reasons why CSF IgG may be 
increased without active CNS infection. These tests are particularly 
problematic in the setting of the immune dysregulation that accompanies 
HIV. We sought to identify clinical features suggestive of VZV and factors 
influencing the detection of VZV DNA in the CSF.  Our study found that many 
patients with positive VZV PCR meet the clinical case definition for TBM and 
that these cases cannot be reliably distinguished on CSF parameters or a 
positive PCR. The differential diagnosis of VZV CNS infection is broad and 
includes other treatable infections. Care should be taken to adequately 
exclude these causes especially TBM in areas of high prevalence. In a 
setting of high TB/HIV prevalence, it remains difficult to distinguish between 
TBM and CNS varicella on clinical and laboratory parameters, despite the 
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